Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1389-1399 |
| Number of pages | 11 |
| Journal | European Journal of Immunology |
| Volume | 48 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection. / Jofra, T; Di Fonte, R; Galvani, Giuseppe; Kuka, M; Iannacone, M; Battaglia, M; Fousteri, G.
In: European Journal of Immunology, Vol. 48, No. 8, 2018, p. 1389-1399.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tr1 cell immunotherapy promotes transplant tolerance via de novo Tr1 cell induction in mice and is safe and effective during acute viral infection
AU - Jofra, T
AU - Di Fonte, R
AU - Galvani, Giuseppe
AU - Kuka, M
AU - Iannacone, M
AU - Battaglia, M
AU - Fousteri, G
PY - 2018
Y1 - 2018
N2 - Tr1 cell therapy is considered an emerging approach to improve transplant tolerance and enhance allogeneic graft survival. However, it remains unclear how Tr1 cells promote transplant tolerance and whether they will be safe and stable in the face of an acute viral infection. By employing a mouse model of pancreatic islet transplantation, we report that Tr1 cell therapy promoted transplant tolerance via de novo induction of Tr1 cells in the recipients. Acute viral infection with lymphocytic choriomeningitis virus (LCMV) had no impact on Tr1 cell number and function, neither on the Tr1 cells infused nor on the ones induced, and that was reflected in the robust maintenance of the graft. Moreover, Tr1 cell immunotherapy had no detrimental effect on CD8 and CD4 anti-LCMV effector T-cell responses and viral control. Together, these data suggest that Tr1 cells did not convert to effector cells during acute infection with LCMV, maintained transplant tolerance and did not inhibit antiviral immunity. © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
AB - Tr1 cell therapy is considered an emerging approach to improve transplant tolerance and enhance allogeneic graft survival. However, it remains unclear how Tr1 cells promote transplant tolerance and whether they will be safe and stable in the face of an acute viral infection. By employing a mouse model of pancreatic islet transplantation, we report that Tr1 cell therapy promoted transplant tolerance via de novo induction of Tr1 cells in the recipients. Acute viral infection with lymphocytic choriomeningitis virus (LCMV) had no impact on Tr1 cell number and function, neither on the Tr1 cells infused nor on the ones induced, and that was reflected in the robust maintenance of the graft. Moreover, Tr1 cell immunotherapy had no detrimental effect on CD8 and CD4 anti-LCMV effector T-cell responses and viral control. Together, these data suggest that Tr1 cells did not convert to effector cells during acute infection with LCMV, maintained transplant tolerance and did not inhibit antiviral immunity. © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
U2 - 10.1002/eji.201747316
DO - 10.1002/eji.201747316
M3 - Article
VL - 48
SP - 1389
EP - 1399
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - 8
ER -